7 brokerages have issued 12 month price objectives for Solid Biosciences' shares. Solid Biosciences (SLDB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.In a report issued on May 18, Christopher Marai from Nomura maintained a Buy rating on Solid Biosciences (SLDB), with a price target ...[...]Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical HoldSolid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical HoldSolid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of DirectorsSolid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of DirectorsSolid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020 On average, they expect Solid Biosciences' stock price to reach $33.60 in the next twelve months. Investors have identified the Drug Manufacturers – Specialty & Generic company Solid Biosciences Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. This suggests a possible upside of 266.0% from the stock's current price. The recovery is faltering, top forecasters say Find the latest Solid Biosciences Inc. (SLDB) stock quote, history, news and other vital information to help you with your stock trading and investing. Solid Biosciences is a life science company focused on developing transformative treatments to improve the lives of patients living with Duchenne muscular dystrophy (Duchenne). Touch device users, explore by touch or with swipe gestures. Solid Biosciences stock price target raised to $10 from $6 at Instinet Dec. 19, 2019 at 8:39 a.m. View recent trades and share price information for Solid Biosciences Inc USD0.001 Their predictions range from $8.00 to $57.00. The SLDB stock’s 52-week price range has touched low of $1.96 and a $13.58 high. Solid Biosciences (SLDB) has reported weaker-than-expected 1Q20 results, with FY GAAP EPS of -$2.91 missing Street consensus by $0.09. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. Solid Biosciences Inc. Common Stock (SLDB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Cambridge, MA 02139
Log in to see them here or sign up to get started.Create a list of the investments you want to track.Visit a quote page and your recently viewed tickers will be displayed here.Radius Health Licensing Deal, And Other News: The Good, Bad And Ugly Of BiopharmaFDA maintains clinical hold on Solid Bio's Ignite DMD trialSarepta (SRPT) is seeking accelerated approval for its third exon-skipping therapy, casimersen, for DMD patients.Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose. Stock analysis for Solid Biosciences Inc (SLDB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. However the update for …
U.S. budget deficit equals $2.18 trillion in first 10 months of fiscal 2020 View Analyst Price Targets for Solid Biosciences.